替硝唑是一种口服抗菌剂，是一种 5-硝基咪唑，对厌氧菌和原生动物具有选择性活性。
| Cas No. | 19387-91-8 |
| 别名 | 替硝唑 |
| 化学名 | 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole |
| Canonical SMILES | CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C |
| 分子式 | C8H13N3O4S |
| 分子量 | 247.27 |
| 溶解度 | ≥ 11.25mg/mL in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Tinidazole is a synthesized imidazole derivative used in antiprotozoal treatment with antiamebic and antibacterial properties.Target: AntibacterialTinidazole is a 5-nitroimidazole active in vitro against a wide variety of anaerobic bacteria and protozoa. Tinidazole is an effective treatment against anaerobic microorganisms based on its pharmacokinetic characteristics (C(max) 51 microg/ml, t(1/2) 12.5 h) and its excellent in vitro activity. Its long half-life allows once a day regimens. Tinidazole is as effective as metronidazole in the treatment of infections caused by T. vaginalis, giardiasis and amebiasis and bacterial vaginosis, malaria, odontogenic infections, anaerobic bacterial infections (pelvic inflammatory disease, diabetic foot), surgical prophylaxis (abdominal and hysterectomy) and Helicobacter pylori eradication. Tinidazole has recently been resurrected and FDA approved for trichomoniasis and BV in the USA and is being restudied as an alternative to metronidazole for BV. In vitro antimicrobial activity and pharmacokinetics studies indicate that when compared directly with metronidazole, tinidazole has minor but possibly relevant antimicrobial as well as pharmacokinetic advantages. References:
[1]. Granizo JJ, et al. Tinidazole: a classical anaerobical drug with multiple potential uses nowadays. Rev Esp Quimioter. 2009 Jun;22(2):106-14.
[2]. Nailor MD, et al. Tinidazole for bacterial vaginosis. Expert Rev Anti Infect Ther. 2007 Jun;5(3):343-8. |
